Form 8-K - Current report:
SEC Accession No. 0001835268-26-000019
Filing Date
2026-05-12
Accepted
2026-05-12 09:02:24
Documents
12
Period of Report
2026-05-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K cntb-20260512.htm   iXBRL 8-K 26809
2 EX-99.1 cntbq12026earningsrelease.htm EX-99.1 57508
  Complete submission text file 0001835268-26-000019.txt   213078

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cntb-20260512.xsd EX-101.SCH 1806
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cntb-20260512_lab.xml EX-101.LAB 22498
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cntb-20260512_pre.xml EX-101.PRE 13245
16 EXTRACTED XBRL INSTANCE DOCUMENT cntb-20260512_htm.xml XML 2828
Mailing Address 3580 CARMEL MOUNTAIN ROAD, SUITE 200 SAN DIEGO CA 92130
Business Address 3580 CARMEL MOUNTAIN ROAD, SUITE 200 SAN DIEGO CA 92130 858-727-1040
Connect Biopharma Holdings Ltd (Filer) CIK: 0001835268 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40212 | Film No.: 26966100
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)